319 related articles for article (PubMed ID: 28197632)
1. PGRMC1-dependent autophagy by hyperoside induces apoptosis and sensitizes ovarian cancer cells to cisplatin treatment.
Zhu X; Ji M; Han Y; Guo Y; Zhu W; Gao F; Yang X; Zhang C
Int J Oncol; 2017 Mar; 50(3):835-846. PubMed ID: 28197632
[TBL] [Abstract][Full Text] [Related]
2. Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1.
Peluso JJ; Liu X; Saunders MM; Claffey KP; Phoenix K
J Clin Endocrinol Metab; 2008 May; 93(5):1592-9. PubMed ID: 18319313
[TBL] [Abstract][Full Text] [Related]
3. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
4. Progesterone receptor membrane component-1 regulates the development and Cisplatin sensitivity of human ovarian tumors in athymic nude mice.
Peluso JJ; Gawkowska A; Liu X; Shioda T; Pru JK
Endocrinology; 2009 Nov; 150(11):4846-54. PubMed ID: 19797399
[TBL] [Abstract][Full Text] [Related]
5. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
Washington MN; Suh G; Orozco AF; Sutton MN; Yang H; Wang Y; Mao W; Millward S; Ornelas A; Atkinson N; Liao W; Bast RC; Lu Z
Cell Death Dis; 2015 Aug; 6(8):e1836. PubMed ID: 26247722
[TBL] [Abstract][Full Text] [Related]
6. Hyperoside induces both autophagy and apoptosis in non-small cell lung cancer cells in vitro.
Fu T; Wang L; Jin XN; Sui HJ; Liu Z; Jin Y
Acta Pharmacol Sin; 2016 Apr; 37(4):505-18. PubMed ID: 26948085
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH
Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716
[TBL] [Abstract][Full Text] [Related]
8. ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells.
Xie Q; Su J; Jiao B; Shen L; Ma L; Qu X; Yu C; Jiang X; Xu Y; Sun L
Int J Oncol; 2016 Dec; 49(6):2507-2519. PubMed ID: 27748803
[TBL] [Abstract][Full Text] [Related]
9. 8‑bromo‑7‑methoxychrysin induces apoptosis by regulating Akt/FOXO3a pathway in cisplatin‑sensitive and resistant ovarian cancer cells.
Ding Q; Chen Y; Zhang Q; Guo Y; Huang Z; Dai L; Cao S
Mol Med Rep; 2015 Oct; 12(4):5100-8. PubMed ID: 26151347
[TBL] [Abstract][Full Text] [Related]
10. Icariin enhances the chemosensitivity of cisplatin‑resistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway.
Jiang S; Chang H; Deng S; Fan D
Int J Oncol; 2019 Jun; 54(6):1933-1942. PubMed ID: 31081049
[TBL] [Abstract][Full Text] [Related]
11. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
Chock KL; Allison JM; Shimizu Y; ElShamy WM
Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
[TBL] [Abstract][Full Text] [Related]
12. shRNA-mediated AMBRA1 knockdown reduces the cisplatin-induced autophagy and sensitizes ovarian cancer cells to cisplatin.
Li X; Zhang L; Yu L; Wei W; Lin X; Hou X; Tian Y
J Toxicol Sci; 2016 Feb; 41(1):45-53. PubMed ID: 26763392
[TBL] [Abstract][Full Text] [Related]
13. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling.
Wang M; Ma X; Wang J; Wang L; Wang Y
Int J Oncol; 2014 Apr; 44(4):1401-9. PubMed ID: 24535252
[TBL] [Abstract][Full Text] [Related]
15. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
16. In vitro inhibition of SKOV-3 cell migration as a distinctive feature of progesterone receptor membrane component type 2 versus type 1.
Albrecht C; Huck V; Wehling M; Wendler A
Steroids; 2012 Dec; 77(14):1543-50. PubMed ID: 23064006
[TBL] [Abstract][Full Text] [Related]
17. PGRMC1 contributes to doxorubicin-induced chemoresistance in MES-SA uterine sarcoma.
Lin ST; May EW; Chang JF; Hu RY; Wang LH; Chan HL
Cell Mol Life Sci; 2015 Jun; 72(12):2395-409. PubMed ID: 25596698
[TBL] [Abstract][Full Text] [Related]
18. Progesterone protects ovarian cancer cells from cisplatin-induced inhibitory effects through progesterone receptor membrane component 1/2 as well as AKT signaling.
Zhu X; Han Y; Fang Z; Wu W; Ji M; Teng F; Zhu W; Yang X; Jia X; Zhang C
Oncol Rep; 2013 Nov; 30(5):2488-94. PubMed ID: 23970345
[TBL] [Abstract][Full Text] [Related]
19. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest.
Zhang D; Piao HL; Li YH; Qiu Q; Li DJ; Du MR; Tsang BK
Exp Mol Pathol; 2016 Jun; 100(3):506-13. PubMed ID: 27163202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
